NEW ORLEANS — A second phase 3 trial of deuruxolitinib confirmed the efficacy and tolerability of the drug in adults with moderate to severe alopecia areata, according to a study presented at the American Academy of Dermatology Annual Meeting.
The data were presented from THRIVE-AA2, a double-blind, placebo controlled phase 3 clinical trial. It evaluated deuruxolitinib, (CTP-543; Concert Pharmaceuticals), an oral Janus kinase inhibitor for moderate to severe alopecia.
Randomly assigned 8 mg to patients suffering from hair loss of 50% or more were those who had a greater percentage.
